Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.
OSMT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Osmotica Pharmaceuticals plc. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 6th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96%. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:
The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 16.84% of free cash flow generating stocks in the Healthcare sector.
The company's compound free cash flow growth rate over the past 2.11 years comes in at -0.31%; that's greater than merely 4.69% of US stocks we're applying DCF forecasting to.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NVST, LUMO, INFU, PHG, and PPD can be thought of as valuation peers to OSMT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Start Time: 16:30 End Time: 17:30 Osmotica Pharmaceuticals plc (OSMT) Q2 2020 Earnings Conference Call August 11, 2020, 16:30 PM ET Company Participants Brian Markison - Chairman and CEO Andrew Einhorn - CFO James Schaub - EVP and COO Derek Cunningham - Director of Optometry and Research, Dell Laser Consultants...
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the ...
Osmotica (OSMT) unit RVL Pharmaceuticals inks an agreement with Santen Pharmaceutical Co. granting the latter exclusive development and commercialization rights to RVL-1201 in Europe, the Middle East, Africa, Japan, China and other Asian countries for the treatment of acquired blepharoptosis (droopy eyelid) in adults.Under the terms of the deal, OSMT...
Shares of Osmotica Pharmaceuticals (NASDAQ: OSMT), a small-cap biopharmaceutical company, are down by 20.4% as of 11:26 a.m. EDT on Tuesday, following the company's announcement on Monday evening of the pricing of a public offering of common stock. Investors aren't thrilled with the prospect of Osmotica resorting to dilutive forms of financing. Osmotica said it would offer 5 million shares to the public for $6.55 per share.